Employee Benefit News March 20, 2025
Dae Y. Lee, Julie Selesnick, Jamie Greenleaf

The recent dismissal of an employee-led class action lawsuit against Johnson & Johnson (J&J), which alleged mismanagement of the health plan’s prescription drug benefit, might give health plan sponsors a false sense of security. Some may assume this means they won’t be held responsible for overseeing their pharmacy benefit managers (PBMs), but that is a dangerous misconception.

This case was dismissed on procedural grounds, not on its merits. Nothing in the court’s ruling reduces or eliminates the fiduciary obligations that health plan sponsors must uphold under ERISA. As a benefits adviser, it has never been more critical to educate your employer clients on their fiduciary responsibilities, including:

  • Scrutinizing PBM agreements to ensure transparency and fairness.
  • Obtaining full PBM compensation...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Pharma, Pharma / Biotech
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
Mark Cuban warns Trump’s tariffs mean his Cost Plus Drugs ‘won’t have a choice’ but to raise prices for consumers
Building for the Healthcare Consumer with Elliot Cohen

Share This Article